TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

Only a minority of myelodysplastic syndrome (MDS) patients respond to hypomethylating agents (HMAs), but strong predictors of response are unknown. We sequenced 40 recurrently mutated myeloid malignancy genes in tumor DNA from 213 MDS patients collected before treatment with azacitidine (AZA) or dec...

Full description

Saved in:
Bibliographic Details
Main Authors: Bejar, Rafael, Lord, Allegra, Stevenson, Kristen, Bar-Natan, Michal, Pérez-Ladaga, Albert, Zaneveld, Jacques, Wang, Hui, Caughey, Bennett, Stojanov, Petar, Getz, Gad, Garcia-Manero, Guillermo, Kantarjian, Hagop, Chen, Rui, Stone, Richard M., Neuberg, Donna, Steensma, David P., Ebert, Benjamin L.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2014
Subjects:
Myeloid Neoplasia
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4208285/
https://ncbi.nlm.nih.gov/pubmed/25224413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-582809
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items